Alzheimer's drug candidate no better than placebo in study

09/16/2008 | Bloomberg

A 12-week study found that AZD3480, an investigational drug from AstraZeneca and Targacept, was just as effective as placebo or standard treatment Aricept in improving cognition in Alzheimer's disease patients. The finding was "affected by the fact that the placebo group showed unexpected improvement over the treatment time, rather than the expected decline," Targacept President and CEO J. Donald deBethizy said.

View Full Article in:

Bloomberg

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Sr. Medical Device Reimbursement Specialist - Regional
Alcon
Fort Worth , TX
Assistant General Counsel/Senior Corporate Counsel - Healthcare Law Group
Genentech
94080, CA
Clinical Trials Agreements Specialist (209955)
The Henry M. Jackson Foundation for the Advancement of Military Medicine Inc.
Rockville, MD
SAFETY, HEALTH, and ENVIRONMENTAL (SHE) REGIONAL SPECIALIST
Matheson Tri-Gas, Inc.
Newark, CA
MANAGER MEDICAL GAS COMPLIANCE AND SAFETY
Matheson Tri-Gas, Inc.
Houston, TX